Cardiol Therapeutics Inc.
CRDL
Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s current work centers on CardiolRx, a pharmaceutically manufactured oral cannabidiol formulation in clinical development for cardiovascular indications, including inflammatory heart conditions. Cardiol Therapeutics also advances related formulations and programs aimed at addressing the biological pathways involved in cardiac inflammation and fibrosis. Its business is concentrated in the biotechnology and pharmaceutical segments of the healthcare market, where it contributes to the development of specialized therapies for serious heart disorders. Based in Oakville, Ontario, Cardiol Therapeutics is positioned as a research-driven company with a narrow therapeutic focus on heart disease treatment.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$0.00
Net Income (TTM)
-C$34M
▲ +7.8% YoY
Op. Margin
–
ROIC
-126.42%
▲ +1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$24M
▲ +4.8% YoY
Op. Cash Flow (TTM)
-C$24M
▼ -8.0% YoY
Net Debt
-C$21M
Net Cash Position
Cash & Equiv.
C$21M
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with CRDL
Cardiol Therapeutics (CRDL) in three numbers
Questions about Cardiol Therapeutics
Is Cardiol Therapeutics a high-quality business?
Cardiol Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$21M, and its weakest is return on capital at -126.4%. The Quality tab shows every check against its target.
Does Cardiol Therapeutics (CRDL) pay a dividend?
No. Cardiol Therapeutics (CRDL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CRDL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.